Skip to main content

and
  1. No Access

    Article

    The transcription factor E2F1 and the SR protein SC35 control the ratio of pro-angiogenic versus antiangiogenic isoforms of vascular endothelial growth factor-A to inhibit neovascularization in vivo

    The transcription factor E2F1 has a crucial role in the control of cell growth and has been shown to regulate neoangiogenesis in a p53-dependent manner through inhibition of activity of the VEGF-A (vascular en...

    G Merdzhanova, S Gout, M Keramidas, V Edmond, J-L Coll, C Brambilla in Oncogene (2010)

  2. No Access

    Article

    Fusogenic membrane glycoproteins induce syncytia formation and death in vitro and in vivo: a potential therapy agent for lung cancer

    Fusogenic membrane glycoproteins (FMGs) are viral envelope proteins, which bind surface receptors and induce fusion of the cell membrane. An FMG-transfected cell will fuse with neighbor cells, thus forming syn...

    E-H Lin, C Salon, E Brambilla, D Lavillette, J Szecsi, F-L Cosset in Cancer Gene Therapy (2010)

  3. No Access

    Article

    Non-invasive in vivo optical imaging of the lacZ and luc gene expression in mice

    The bacterial lacZ gene encoding for β-galactosidase (β-gal) is a common reporter gene used in transgenic mice. Nonetheless, the absence of fluorigenic substrates usable in live animals greatly hampered the non-i...

    V Josserand, I Texier-Nogues, P Huber, M-C Favrot, J-L Coll in Gene Therapy (2007)

  4. No Access

    Article

    Intercellular trafficking and enhanced in vivo antitumour activity of a non-virally delivered P27-VP22 fusion protein

    VP22, a structural protein from herpes simplex virus type I, exhibits the unique property of intercellular trafficking. This protein is exported from primary expressing cells and subsequently imported into nei...

    D Zavaglia, M-C Favrot, B Eymin, C Tenaud, J-L Coll in Gene Therapy (2003)

  5. No Access

    Article

    Cell cycle arrest is sufficient for p53-mediated tumor regression

    p53 gene therapy can induce tumor regression, but the low efficacy of in vivo gene transfer has greatly hampered the mechanistic analysis of this antitumoral activity. We therefore used a p53-null human NSCLC cel...

    L Dubrez, J-L Coll, A Hurbin, F de Fraipont, S Lantejoul, M-C Favrot in Gene Therapy (2001)

  6. No Access

    Article

    Cell death and cancer: replacement of apoptotic genes and inactivation of death suppressor genes in therapy

    This review provides a critical evaluation of the increasing use of gene therapy in the treatment of malignancies to induce active cell death (ACD, apoptosis). This approach is consistent with the notion that ...

    M Favrot, J-L Coll, N Louis, A Negoescu in Gene Therapy (1998)

  7. No Access

    Article

    Long-term survival of immunocompetent rats with intraperitoneal colon carcinoma tumors using herpes simplex thymidine kinase/ganciclovir and IL-2 treatments

    We evaluated the gain in long-term survival of BDIX rats bearing DHDProB colon cancer developed in the peritoneal cavity after in vivo therapy with the tk gene and GCV. The sensitivity and the bystander effect...

    J-L Coll, M Mesnil, M-F Lefebvre, A Lancon, MC Favrot in Gene Therapy (1997)

  8. No Access

    Article

    Clinical relevance of TRKA expression on neuroblastoma: comparison with N-MYC amplification and CD44 expression

    TRKA expression was evaluated on 122 untreated neuroblastomas by immunohistochemistry using an antibody with predetermined specificity. This procedure is simple and reliable for protein detection at cellular l...

    V Combaret, N Gross, C Lasset, K Balmas, R Bouvier, D Frappaz in British Journal of Cancer (1997)

  9. No Access

    Article

    In vitro targeting and specific transfection of human neuroblastoma cells by chCE7 antibody-mediated gene transfer

    We developed a new vector for gene targeting of neuroblastoma (NB) cells, based on the utilization of a monoclonal antibody (chCE7) covalently linked to polylysine (PL). In the presence of chloroquine, chCE7–P...

    J-L Coll, E Wagner, V Combaret, K Metchler, H Amstutz, I Iacono-Di-Cacito in Gene Therapy (1997)